---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-026877"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:54:54.161346+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Candel accelerates unveiling of second enLIGHTEN candidate to AACR April 2024

## Summary
- Second enLIGHTEN platform candidate to be presented at AACR April 9, 2024; originally planned for Q3 2024.
- First-in-class multimodal immunotherapy designed to induce tertiary lymphoid structures for solid tumors.
- Abstract LB263; poster session on Tuesday April 9, 9:00 AM - 12:30 PM PT in San Diego.
- Candidate follows Alpha 201-macro-1; data from preclinical models shown at SITC 2023 and Oncolytic Virus Conference 2023.

## SEC filing metadata
- accession: 0000950170-24-026877
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017024026877/0000950170-24-026877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017024026877/cadl-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-026877
- JSON: https://secwatch.observer/filing/0000950170-24-026877.json
- Plain text: https://secwatch.observer/filing/0000950170-24-026877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.